Boston, MANCT06861088Now EnrollingIRB Ready

Venous Thromboembolism Clinical Trial in Boston, MA

Access cutting-edge venous thromboembolism treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Quercis Pharma AG

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access venous thromboembolism specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related venous thromboembolism treatment provided free

Apply for This Boston Location

Check if you qualify for this venous thromboembolism clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Venous Thromboembolism Study in Boston

The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.

Sponsor: Quercis Pharma AG

Who Can Participate

Inclusion Criteria

Participants must have histological or cytological confirmed pancreatic adenocarcinoma malignancy that is metastatic (including recurrent with distant metastases) or locally advanced.
Receiving first line chemotherapy (within 45 days of first dose of study drug) Note: subjects must be either initiating first systemic cancer therapy regimen following initial diagnosis or initiating first cycle of chemotherapy for disease recurrence.
Minimum age 18 years.
Life expectancy of greater than 4 months.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Participants must have preserved organ and marrow function as defined by:
Platelet count ≥ 100,000/mcL.
Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5x institutional upper limit of normal (ULN).
Total bilirubin ≤ 3x ULN without liver metastases and \< 5x ULN in presence of liver metastases.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN without liver metastases and \< 5x ULN in the presence of liver metastases
Estimated creatinine clearance (CrCl \> 30 mL/min).
Willingness of women of child-bearing potential and men to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until at least 4 weeks after study completion.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Participants with known brain metastases
Prior history of documented thromboembolic event within the last 12 months (excluding central line associated events whereby patients completed anticoagulation)
Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)
History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months
Familial bleeding diathesis
Known diagnosis of disseminated intravascular coagulation (DIC)
Currently receiving anticoagulant therapy
Current daily use of aspirin (\> 100mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g. ibuprofen \> 800mg daily or equivalent)
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Known intolerance to the active ingredient of Kinisoquin™, isoquercetin, nicotinic acid, or ascorbic acid (including known G6PD deficiency)
Females of child-bearing potential who are lactating, have a positive pregnancy test at Screening, or are unwilling to use acceptable contraception prior to study entry and for the duration of study participation until at least 4 weeks after study completion.
Participation in other clinical trials The study is open to any individual who has a metastatic or locally advanced pancreatic adenocarcinoma malignancy without discrimination based on race, religion, political affiliation, or other criteria.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06861088) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Venous Thromboembolism Treatment Options in Boston, MA

If you're searching for venous thromboembolism treatment options in Boston, MA, this clinical trial (NCT06861088) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced venous thromboembolism specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all venous thromboembolism clinical trials near you to find additional studies recruiting in your area.

More Deep Vein Thrombosis Trials in Boston, MA

See all deep vein thrombosis clinical trials recruiting in Boston — not just this study.

Browse Deep Vein Thrombosis Trials in Boston →

Browse More Trials by Condition

Deep Vein Thrombosis TrialsVenous Thromboembolism TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA